Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 410 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv410
  2. Study sites revised (340)v409
  3. Study sites revised (340)v408
  4. Study sites revised (340)v407
  5. Study sites: 341 to 340v406
  6. Study completion pushed from Mar 10, 2026 to Mar 10, 2027
    • Study sites revised (341)
    v405
  7. 8 versions Re-verified since Mar 11, 2026, no change to tracked fieldsv397-v404
  8. Study sites revised (341)v396
  9. 4 versions Re-verified since Mar 4, 2026, no change to tracked fieldsv392-v395
  10. Study sites revised (341)v391
  11. Re-verified, no change to tracked fieldsv390
  12. Study sites revised (341)v389
  13. Study sites revised (341)v388
  14. Study sites revised (341)v387
  15. Study sites revised (341)v386
  16. Study completion date: Feb 22, 2025 to Mar 10, 2026
    • Study sites revised (341)
    v385
  17. Re-verified, no change to tracked fieldsv384
  18. Study sites revised (341)v383
  19. Study sites revised (341)v382
  20. Study sites revised (341)v381
  21. Study sites revised (341)v380
  22. Study sites revised (341)v379
  23. Study sites revised (341)v378
  24. Re-verified, no change to tracked fieldsv377
  25. Study sites revised (341)v376
  26. Study sites revised (341)v375
  27. Study sites revised (341)v374
  28. Study sites revised (341)v373
  29. Study sites revised (341)v372
  30. Study completion date: Feb 22, 2025v371
  31. Re-verified, no change to tracked fieldsv370
  32. Study sites revised (341)v369
  33. Study sites revised (341)v368
  34. Re-verified, no change to tracked fieldsv367
  35. Study sites revised (341)v366
  36. Re-verified, no change to tracked fieldsv365
  37. Site details revised at 1 of 341 sitesv364
  38. Study sites revised (341)v363
  39. Re-verified, no change to tracked fieldsv362
  40. Study sites revised (341)v361
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized phase IIB trial studies imatinib mesylate at two different doses and dasatinib to see how well they work in treating patients with previously untreated chronic phase chronic myelogenous leukemia. Imatinib mesylate or dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Trial Details
NCT Number NCT00070499
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Chronic Myeloid Leukemia, BCR-ABL1 Positive
Related terms Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Enrollment 406 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov